Elevation Pharmaceuticals Raises $17m Second Tranche of Series A Financing

Elevation Pharmaceuticals, a San Diego, CA-based biopharmaceutical company focused on the development of new aerosol therapies for patients with respiratory diseases, has drawn down a $17m second tranche of its Series A financing.

Backers include all of the original participants in the round including Canaan Partners, Care Capital, TPG Biotech, and Mesa Verde Venture Partners.

Elevation presented positive results of a Phase 2a study and has initiated a Phase 2b study of EP-101 in patients with moderate to severe chronic obstructive pulmonary disease (COPD). EP-101 is a proprietary inhalation solution formulation of glycopyrrolate, a long-acting muscarinic antagonist (LAMA), delivered by an optimized, Investigational eFlow® Nebulizer System (PARI Pharma GmbH).

The company is led by President and CEO Bill Gerhart and Senior Vice President and Chief Medical Officer Dr. Ahmet Tutuncu, Elevation Pharmaceuticals.



Join the discussion